Former FDA Official Criticizes COVID-19 Guidance’s Silence On Biosimilars
Eva Temkin Highlights Unanswered Questions On 180-Day Exclusivity
Former senior FDA official Eva Temkin has criticized the FDA’s silence on the development of biosimilars and interchangeable products in its recent COVID-19 guidance, suggesting that the agency’s stance on 180-day exclusivity for small-molecule generics could be extended to interchangeability exclusivity for biosimilars, while also pointing out that key questions around generic exclusivity are left unanswered
You may also be interested in...
Eden Biologics adds Henlius’ Scott Liu to its board of directors, as both King & Spalding and Gedeon Richter also make fresh appointments. And Stada has extended the tenure of CEO Peter Goldschmidt.
Details of how the FDA plans to conduct remote evaluations of manufacturing facilities during the COVID-19 pandemic have been set out in guidance published by the US agency.
Viatris and partner Biocon have seen FDA action on their application for a bevacizumab biosimilar rival to Avastin delayed by the need for a facility inspection, the timing of which is uncertain due to coronavirus-related restrictions.